Want to see XCUR full AI Analyst Report?
Exicure (XCUR) AI Stock Analysis
Exicure
(NASDAQ:XCUR)
The overall score is low primarily because Exicure’s financial profile is very weak, with no current revenue, recurring losses, eroded equity, and heavy ongoing cash burn that create substantial funding and sustainability risk. Additional pressure comes from Nasdaq compliance issues and the risk of potential delisting, which weigh on the stock’s risk‑reward profile. Technical indicators show a generally bearish trend without strong downside momentum, and valuation is unsupported by positive earnings or dividends, leaving the investment case highly speculative.
Exicure (XCUR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 44.74K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.33
- Revenue Growth
- ―
- EPS Growth
- 23.05%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Exicure Business Overview & Revenue Model
Company Description
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combi...
How the Company Makes Money
Exicure did not have a sustained commercial product revenue base; its business model was primarily R&D-driven. The company’s cash inflows historically were mainly from financing activities (e.g., issuing equity and related capital-raising transaction...
Exicure Financial Statement Overview
Summary
Financial performance is extremely weak: Exicure is effectively pre‑revenue with the latest TTM showing no revenue and sizeable operating and net losses, equity and assets have eroded materially despite no current debt, and cash flow shows persistent, significant cash burn with negative operating and free cash flow in every period. These factors make the company highly dependent on external financing and future pipeline success.
Income Statement
8Very NegativeBalance Sheet
32NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 500.00K | 0 | 28.83M | -483.00K |
| Gross Profit | -263.00K | -460.00K | 500.00K | -1.42M | 26.97M | -483.00K |
| EBITDA | -8.55M | -5.12M | -8.85M | -15.54M | 78.00K | -60.63M |
| Net Income | -8.28M | -4.95M | -9.70M | -16.91M | -2.58M | -64.10M |
Balance Sheet | ||||||
| Total Assets | 11.40M | 14.04M | 15.06M | 11.58M | 23.33M | 64.87M |
| Cash, Cash Equivalents and Short-Term Investments | 1.72M | 3.75M | 12.51M | 816.00K | 8.58M | 39.14M |
| Total Debt | 0 | 176.00K | 5.93M | 6.67M | 7.31M | 14.74M |
| Total Liabilities | 10.42M | 10.12M | 8.28M | 8.55M | 8.41M | 53.64M |
| Stockholders Equity | 977.00K | 3.93M | 6.77M | 3.03M | 14.92M | 11.23M |
Cash Flow | ||||||
| Free Cash Flow | -6.38M | -8.56M | -2.91M | -10.36M | -35.67M | -35.79M |
| Operating Cash Flow | -6.70M | -8.55M | -2.91M | -10.36M | -35.66M | -34.82M |
| Investing Cash Flow | 563.00K | -1.81M | 0 | -1.08M | 4.70M | 43.09M |
| Financing Cash Flow | 0 | 1.60M | 13.40M | 3.67M | -3.10M | 1.12M |
Exicure Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XCUR, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.19, and below the 200-day MA of 2.69, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.05 is Neutral, neither overbought nor oversold. The STOCH value of 27.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XCUR.
Exicure Risk Analysis
Exicure disclosed 22 risk factors in its most recent earnings report. Exicure reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskExicure Peers Comparison
Overall Rating
- XCUR42Neutral
UNCY41Neutral
CRBU38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| XCUR | 42Neutral | $6.61M | -0.78 | -237.91% | ― | ― | 23.05% |
| UNCY | 41Neutral | $104.18M | -2.08 | -88.81% | ― | ― | 43.63% |
| CRBU | 38Underperform | $45.37M | -0.41 | -89.11% | ― | 10.02% | 39.66% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XCUR | Exicure | 1.02 | -3.21 | -75.89% | |
| UNCY | Unicycive Therapeutics, Inc. | 3.49 | -0.95 | -21.40% | |
| CRBU | Caribou Biosciences, Inc. | 0.44 | -1.73 | -79.77% |
Exicure Corporate Events
Exicure Receives Nasdaq Extension Amid Ongoing Listing Risk
NegativeOn June 5, 2026, Exicure, Inc. was notified by Nasdaq that it was not in compliance with Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and that it also failed to meet alternative continued listing standa...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 16, 2026